ODE models for oncolytic virus dynamics.
暂无分享,去创建一个
[1] Natalia L. Komarova,et al. Computational Biology of Cancer: Lecture Notes and Mathematical Modeling , 2005 .
[2] C. O'Shea,et al. Viruses – seeking and destroying the tumor program , 2005, Oncogene.
[3] Artem S Novozhilov,et al. Population models with singular equilibrium. , 2006, Mathematical biosciences.
[4] J. Bell,et al. Oncolytic viruses: what's next? , 2007, Current cancer drug targets.
[5] J. Kaplan,et al. Adenovirus-based cancer gene therapy. , 2005, Current gene therapy.
[6] Dominik Wodarz,et al. Gene therapy for killing p53-negative cancer cells: use of replicating versus nonreplicating agents. , 2003, Human gene therapy.
[7] J. Bell,et al. Recent progress in the battle between oncolytic viruses and tumours , 2005, Nature Reviews Cancer.
[8] Eugene V Koonin,et al. Mathematical modeling of tumor therapy with oncolytic viruses: Regimes with complete tumor elimination within the framework of deterministic models , 2006, Biology Direct.
[9] Zeljko Bajzer,et al. Mathematical modeling of cancer radiovirotherapy. , 2006, Mathematical biosciences.
[10] M. Nowak,et al. Virus dynamics: Mathematical principles of immunology and virology , 2001 .
[11] H. McCallum,et al. How should pathogen transmission be modelled? , 2001, Trends in ecology & evolution.
[12] Zeljko Bajzer,et al. Modeling of cancer virotherapy with recombinant measles viruses. , 2008, Journal of theoretical biology.
[13] Nicola Bellomo,et al. A Survey of Models for Tumor-Immune System Dynamics , 1996 .
[14] S. Hotte,et al. Overview of phase I studies of intravenous administration of PV701, an oncolytic virus. , 2003, Current opinion in molecular therapeutics.
[15] S. Russell,et al. History of oncolytic viruses: genesis to genetic engineering. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.
[16] D. Kirn,et al. From ONYX-015 to armed vaccinia viruses: the education and evolution of oncolytic virus development. , 2007, Current cancer drug targets.
[17] D. Wodarz,et al. Viruses as antitumor weapons: defining conditions for tumor remission. , 2001, Cancer research.
[18] M. Vähä-Koskela,et al. Oncolytic viruses in cancer therapy , 2007, Cancer Letters.
[19] Jianjun Paul Tian,et al. Glioma virotherapy: effects of innate immune suppression and increased viral replication capacity. , 2006, Cancer research.
[20] B. Fang,et al. Oncolytic virotherapy for cancer treatment: challenges and solutions , 2005, The journal of gene medicine.
[21] F. McCormick,et al. Cancer Specific Viruses and the Development of ONYX-015 , 2003, Cancer biology & therapy.
[22] J. Bell,et al. Getting oncolytic virus therapies off the ground. , 2003, Cancer cell.
[23] Robert A. Gatenby,et al. Mathematical Modeling in Cancer , 2010 .
[24] Dominik Wodarz,et al. Towards Predictive Computational Models of Oncolytic Virus Therapy: Basis for Experimental Validation and Model Selection , 2009, PloS one.
[25] M. Roberts,et al. Naturally oncolytic viruses. , 2006, Current opinion in molecular therapeutics.
[26] Karl Sigmund,et al. Kolmogorov and population dynamics , 2007 .
[27] Hyunsuk Shim,et al. Cancer scene investigation: how a cold virus became a tumor killer. , 2005, Future oncology.
[28] Lawrence M Wein,et al. Validation and analysis of a mathematical model of a replication-competent oncolytic virus for cancer treatment: implications for virus design and delivery. , 2003, Cancer research.
[29] D. Kirn,et al. Replicating viruses as selective cancer therapeutics. , 1996, Molecular medicine today.
[30] Frank McCormick,et al. Future prospects for oncolytic therapy , 2005, Oncogene.
[31] R. Martuza,et al. Oncolytic viral therapies – the clinical experience , 2005, Oncogene.
[32] Annick Lesne,et al. Kolmogorov's heritage in mathematics , 2007 .
[33] A. J. Hall. Infectious diseases of humans: R. M. Anderson & R. M. May. Oxford etc.: Oxford University Press, 1991. viii + 757 pp. Price £50. ISBN 0-19-854599-1 , 1992 .
[34] W. Rom,et al. Wild-type adenovirus decreases tumor xenograft growth, but despite viral persistence complete tumor responses are rarely achieved--deletion of the viral E1b-19-kD gene increases the viral oncolytic effect. , 2001, Human gene therapy.